D. Phillips

发表

Souers AJ, Leverson JD, Boghaert ER et al.ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208

L. Lam, C. Tse, Cheol‐Min Park, 2013 .

Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells

E. Hsi, Mitchell R. Smith, J. Bodo, 2016, Oncotarget.

Caveolae Signaling Complex Components into Ceramide-Enriched Clustering of DR 5 and Concentrating Death-Inducing Carcinoma Cells to TRAIL-Induced Apoptosis through Cyclooxygenase-2 Inhibition Sensitizes Human Colon

F. Desmots, J. Houghton, L. Elghazi, 2005 .

A caspase-8-independent component in TRAIL/Apo-2L-induced cell death in human rhabdomyosarcoma cells

J. Houghton, D. Tillman, K. Izeradjene, 2003, Cell Death and Differentiation.

Ceramide induces a loss in cytosolic peroxide levels in mononuclear cells.

H. Griffiths, D. Phillips, 2003, The Biochemical journal.

Ceramide induces a loss of cytosolic peroxide in mononuclear cells

H. Griffiths, D. Phillips, 2003 .

Synthetic ceramides induce growth arrest or apoptosis by altering cellular redox status.

H. Griffiths, D. Phillips, K. Allen, 2002, Archives of biochemistry and biophysics.

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

L. Lam, C. Tse, Cheol‐Min Park, 2013, Nature Medicine.

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

C. Tse, D. Anderson, Daniel J. Anderson, 2015, Cell Death and Disease.

Correction to Structure-Guided Design of a Series of MCL-1 Inhibitors with High Affinity and Selectivity.

Scott A. Erickson, C. Tse, A. Petros, 2015, Journal of medicinal chemistry.

Aberrant reactive oxygen and nitrogen species generation in rheumatoid arthritis (RA): causes and consequences for immune function, cell survival, and therapeutic intervention.

G. Kitas, H. Griffiths, D. Phillips, 2010, Antioxidants & redox signaling.

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Dolores Diaz, Jun Chen, Deepak Sampath, 2015, Science Translational Medicine.

Ceramide-induced G2 arrest in rhabdomyosarcoma (RMS) cells requires p21Cip1/Waf1 induction and is prevented by MDM2 overexpression

J. Hunt, J. Houghton, L. Harris, 2007, Cell Death and Differentiation.

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

L. Lam, J. Leverson, E. Litvinovich, 2016, Blood Cancer Journal.

Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)

L. Lam, J. Leverson, Yu Xiao, 2015, Blood Cancer Journal.

Expanding the Repertoire for “Large Small Molecules”: Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers

Ahmad Y. Sheikh, Richard S. Hong, Geoff G. Z. Zhang, 2021, Molecular Cancer Therapeutics.

Genetically defining the mechanism of Puma- and Bim-induced apoptosis

D. Green, J. Opferman, J. Rehg, 2011, Cell Death and Differentiation.

A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies

M. Konopleva, T. Penning, Y. Tong, 2019, Leukemia.

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models

Jing Wang, M. Konopleva, M. Andreeff, 2019, Haematologica.

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia

Dan Cojocari, Agnieszka E. Gorska, J. Huska, 2021, Haematologica.

Structure-guided design of a series of MCL-1 inhibitors with high affinity and selectivity.

Scott A. Erickson, C. Tse, A. Petros, 2015, Journal of medicinal chemistry.

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity.

Brian J. Smith, C. Tse, A. Petros, 2014, ACS medicinal chemistry letters.

Induction of apoptosis promoted by Bang52; a small molecule that downregulates Bcl-x(L).

G. Zambetti, S. Mazur, M. Rossi, 2009, Bioorganic & medicinal chemistry letters.

Assays to measure p53-dependent and -independent apoptosis.

G. Zambetti, J. R. Jeffers, S. Garrison, 2009, Methods in molecular biology.

The anti‐inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species

K. Woollard, D. C. Phillips, H. Griffiths, 2003, British journal of pharmacology.

5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis

J. Leverson, Dan Cojocari, Sha S. Jin, 2020, Clinical Cancer Research.

MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma

M. Kalady, A. Souers, Xiaoxia Li, 2022, Cell death & disease.

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma

E. Hsi, J. Bodo, A. Souers, 2020, EJHaem.

Inhibition of Cyclin Dependent Kinase 9 Synergistically Enhanced Venetoclax Activity in Mantle Cell Lymphoma Cells

E. Hsi, J. Bodo, A. Souers, 2016 .

CDK9 Inhibition Reverses Resistance to ABT-199 (GDC-0199) By Down-Regulating MCL-1

T. Penning, Y. Tong, J. Leverson, 2014 .

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

Xin Lu, J. Leverson, W. N. Pappano, 2015, Molecular Cancer Therapeutics.

Direct modulatory effect of C‐reactive protein on primary human monocyte adhesion to human endothelial cells

K. Woollard, D. Phillips, H. Griffiths, 2002, Clinical and experimental immunology.

Abbv-621 Is a Novel and Potent TRAIL Receptor Agonist Fusion Protein That Induces Apoptosis Alone and in Combination with Navitoclax and Venetoclax in Hematological Tumors

S. Morgan-Lappe, Dong Cheng, S. Tahir, 2017 .

Structure-Based Design of A-1293102, a Potent and Selective BCL-XL Inhibitor.

Chaohong Sun, Z. Tao, P. Kovar, 2021, ACS medicinal chemistry letters.

Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors

Xin Lu, Li Zhou, S. Morgan-Lappe, 2021, Cancer Research.

Cyclooxygenase-2 inhibition sensitizes human colon carcinoma cells to TRAIL-induced apoptosis through clustering of DR5 and concentrating death-inducing signaling complex components into ceramide-enriched caveolae.

F. Desmots, J. Houghton, L. Elghazi, 2005, Cancer research.

Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL Inhibitor

Xiaohong Song, Z. Tao, P. Kovar, 2020, ACS medicinal chemistry letters.

The Combinatorial Activity of Eftozanermin (ABBV-621), a Novel and Potent TRAIL Receptor Agonist Fusion Protein, in Pre-Clinical Models of Hematologic Malignancies

S. Tahir, Haichao Zhang, Sha S. Jin, 2020 .

Sphingosine-induced apoptosis in rhabdomyosarcoma cell lines is dependent on pre-mitochondrial Bax activation and post-mitochondrial caspases.

J. Houghton, Sophie Martin, B. Doyle, 2007, Cancer research.

Free radicals and redox signalling in T-cells during chronic inflammation and ageing.

G. Kitas, H. Griffiths, M. Grant, 2011, Biochemical Society transactions.

Balancing Properties with Carboxylates: A Lead Optimization Campaign for Selective and Orally Active CDK9 Inhibitors.

K. Longenecker, T. Penning, Y. Tong, 2021, ACS medicinal chemistry letters.

Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia

Steven M. Chan, J. Leverson, Brandon Nicolay, 2021, Leukemia.

Combination of Enasidenib and Venetoclax Shows Superior Anti-Leukemic Activity Against IDH2 Mutated AML in Patient-Derived Xenograft Models

Steven M. Chan, J. Leverson, Brandon Nicolay, 2018, Blood.

Targeting MAPK Signaling Pathway with Cobimetinib (GDC-0973) Enhances Anti-Leukemia Efficacy of Venetoclax (ABT-199/GDC-0199) in Acute Myeloid Leukemia Models

M. Konopleva, M. Andreeff, H. Kantarjian, 2016 .

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor

Xin Lu, J. Leverson, S. Elmore, 2015, Molecular Cancer Therapeutics.

Free radicals and redox signalling in T-cells during chronic inflammation and ageing.

G. Kitas, H. Griffiths, M. Grant, 2011, Biochemical Society Transactions.

Pevonedistat, a Nedd-8 Activating Enzyme Inhibitor, Upregulates NOXA to Increase Effectiveness of Azacitidine and Venetoclax in Preclinical Models of Acute Myelogenous Leukemia

J. Leverson, Dan Cojocari, E. Boghaert, 2019, Blood.

Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients

L. Lam, M. Mitten, Haichao Zhang, 2023, Communications medicine.